Norwalk Leslie V 4

What Happened Leslie V. Norwalk, a director of Neurocrine Biosciences (NBIX), sold 1,250 shares on June 4, 2026, for total proceeds of approximately $210,072. The weighted-average sale price was $168.06 per share; individual trades occurred at prices between $168.00 and $168.2550. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: June 4, 2026 (reported on Form 4 filed June 8, 2026).
• Type: Open-market sale (code S).
• Shares sold: 1,250; weighted average price: $168.06; total proceeds ≈ $210,072.
• Sale executed by a broker pursuant to a Rule 10b5-1 trading plan adopted Sept 15, 2025; issuer policy prevents amending the plan after adoption (Footnote F1).
• Shares were sold in multiple trades at $168.00–$168.2550; issuer/filing will provide breakdown on request (Footnote F2).
• Shares owned after transaction: not specified in the provided filing.

Context The sale was effected under a pre-established 10b5-1 plan, which is commonly used to automate insider sales and reduce concerns about trading on non-public information. The Form 4 was filed within the standard two-business-day window and does not, by itself, indicate the insider’s view of the company.